Ferroptosis Modulator

Parishin B is a multi-target biological agent with anti-epileptic, anti-fascioliasis and anti-breast cancer lung metastasis activities. Parishin B regulates the gene/protein activities of ACLY, unc13c, γ-aminobutynergic system, pro-inflammatory system, antioxidant system, monoaminergic system, ferroptosis-related pathways, as well as GST, CatL, Trx and TRIB3. Parishin B modulates energy-lipid metabolism, synaptic function, neurotransmitter balance, neuroinflammation, oxidative stress, parasite detoxification/invasion processes, as well as apoptosis, cell cycle, proliferation and metastasis of cancer cells^[1][2][3]. Parishin B can be used for related research of epilepsy, fascioliasis and breast cancer lung metastasis^[3].

SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E₂ (PGE₂) and blocks the PGE₂-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease.